Palvella Therapeutics PVLA
NASDAQ PVLA
$157.24 +1.77 (+1.14%)
As of: Sep 4, 2026 · 3:59 PM EDT

Palvella Therapeutics (PVLA) Non Operating Investment Income (2026)

Palvella Therapeutics (PVLA) posted quarterly Non Operating Investment Income of $4000.0 for Q1 2026.

Analysis

Palvella Therapeutics (PVLA) Non Operating Investment Income (2026) Analysis & Trends

Palvella Therapeutics (PVLA) has reported Non Operating Investment Income for 1 consecutive years, with $4000.0 the latest figure, recorded in Q1 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Palvella Therapeutics 2.24 Bn 1.93 Bn - -30,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -30,000.00
Mar 31, 2026 4,000.00